Results 161 to 170 of about 99,358 (330)

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. [PDF]

, 2017
Purpose: Pazopanib, a multireceptor tyrosine kinase inhibitor targeting primarily VEGFRs1–3, is approved for advanced soft tissue sarcoma (STS) and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK inhibitor used for melanoma.
Azad, Nilofe A., Kurzrock, Razelle, Ludwig, Joseph A., Meric-Bernstam, Funda, Meyer, Christian, O\u27Connor, Ashley, Roszik, Jason, Shaw, Kenna, Subbiah, Vivek, Zahurak, Marianna L., Zinner, Ralph G.   +10 more
core   +1 more source

Ototoxicity in Cancer Therapies

Oral Diseases, EarlyView.
Sady Selaimen da Costa, Nathaniel S. Treister, Caio Eddie de Melo Alves   +2 more
wiley   +1 more source

Dental Adverse Effects Following Multimodality Treatment for Head and Neck Rhabdomyosarcoma: Results of a Trans‐Atlantic Multicentre Study

Pediatric Blood &Cancer, Volume 72, Issue 11, November 2025.
ABSTRACT Introduction As survival of paediatric cancer improves, more emphasis is placed on late adverse effects. However, the dental and periodontal adverse effects of cancer treatments in children remain an underinvestigated complication. This study aims to investigate the prevalence of late clinical dental adverse effects (cDAE) in survivors of ...
Koen B. Krommenhoek, Marinka L. F. Hol, Olga Slater, Mark N. Gaze, Willem M. M. Fennis, Frederic J. Kolb, Ludwig Smeele, Daniel J. Indelicato, Reinier C. Hoogeveen, Alfred G. Becking, Johannes H. M. Merks   +10 more
wiley   +1 more source

Pure testicular rhabdomyosarcoma [PDF]

, 1968
F Alexander
openalex   +1 more source

Hold Me Tight Group Intervention for Parents of Children With Cancer

Journal of Family Therapy, Volume 47, Issue 4, November 2025.
ABSTRACT This present article reports on the experiences of parents of children with cancer who participated in an emotionally focused Hold Me Tight (HMT) group intervention. A purposive sample of 24 parents was recruited from 3‐day HMT courses. Focus group conversations were conducted at the end of each course and analysed using Interpretative ...
Krista Koivula, Hannu Kokki, Maija Korhonen, Aarno Laitila, Juho Kalapudas, Kirsi Honkalampi   +5 more
wiley   +1 more source

IA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling

British Journal of Pharmacology, Volume 182, Issue 22, Page 5670-5689, November 2025.
Background and Purpose Dysregulation of the IL‐6/glycoprotein 130(gp130)/STAT3 signalling axis is implicated in several human diseases, particularly cancer. Notably, gp130, a single transducer of this signalling axis, is a target for ovarian cancer treatment. However, data regarding small‐molecule inhibitors of gp130 are lacking. Therefore, we aimed to
Sun‐Ae Park, Hee Jung Kim, Lee Kyung Kim, Hae‐Ri Lee, Bo‐Kyung Jung, Ji Hyeon Kim, Myung Jin Kim, Tae Gwon Oh, Hee Eun Kang, Kye Jung Shin, Jae Hong Seo, Tae‐Hwe Heo   +11 more
wiley   +1 more source

Antigenicity of rhabdomyosarcomas induced by nickel sulfide (Ni3S2) [PDF]

, 1968
Lynette B. Corbeil
openalex   +1 more source

The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β‐Catenin Signaling Pathway

The FASEB Journal, Volume 39, Issue 20, 31 October 2025.
ACTL6A, A new radiosensitizing target for esophageal squamous cell carcinoma? ABSTRACT Actin‐like protein 6A (ACTL6A) is thought to be associated with the survival and prognosis of patients with a variety of human cancers. This study investigates the effect of ACTL6A knockdown on ESCC radiosensitivity and explores molecular mechanisms that may enhance ...
Shuo Zhou, Tongyou Sun, Likun Liu, Dong Guo, Xueyuan Zhang, Wenbin Shen, Shaolin Gao, Shuchai Zhu   +7 more
wiley   +1 more source

A patient with newly diagnosed breast cancer found to have mosaic TP53 likely pathogenic variant

CA: A Cancer Journal for Clinicians, EarlyView.
Hetal D. Mistry, MacKenzie R. Adams, Charu Taneja, Lauren J. Massingham, Elizabeth H. Dibble, Kara L. Leonard, Jesse Hart, Galina G. Lagos, Mary Anne Fenton   +8 more
wiley   +1 more source

PIM1 Attenuates Innate Immunity to Foster Coronavirus Replication through Ubiquitin Ligase β‐TrCP‐Mediated IFNAR1 Degradation

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Hijacking Host Kinase PIM1: A β‐Coronavirus (OC43) strategy to degrade IFNAR1 and evade antiviral immunity. Human β‐coronaviruses (OC43) exploit the proto‐oncoprotein PIM1 kinase to sabotage innate immunity. Viral RNA/proteins upregulate PIM1, which phosphorylates E3 ligase β‐TrCP1.
Qianya Wan, Lin Zhu, Cien Chen, Li Zhong, Houying Leung, Wei Li, Chang Xu, Xi Yao, Huan Hu, Mandi Wu, Yuxin Hou, Hin Chu, Yiran Wang, Sheng Chen, Mingyu Pan, Zongwei Cai, Ming‐liang He   +16 more
wiley   +1 more source